

Amendments to the claims:

Please cancel original claims 1-53 and add new claims 54-80. This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-53 (cancelled)

54. (new) A chemical complex comprising:

i) a beta-2 adrenoceptor agonist; and

ii) an aminosugar selected from the group consisting of glucosamine, mannosamine, salts and derivatives thereof, wherein the derivatives thereof is selected from the group consisting of derivatives wherein the amino group and/or hydroxyl group of the aminosugar is alkylated, arylated or acylated, and wherein the anomeric, 2-, 3-, 4-, or 6-position is sulphated or phosphorylated.

55. (new) A chemical complex according to claim 54, wherein the beta-2 adrenoceptor agonist is selected from the group consisting of bambuterol, bitolterol, broxaterol, carbuterol, clenbuterol, clorprenaline, dioxethedrine, dopexamine, ephedrine, epinephrine, etafedrine, ethylnorepinephrine, fenoterol, formoterol, hexoprenaline, isoetarine, isoproterenol, mabuterol, metaproterenol, methoxyphenamine orciprenaline, pirbuterol, procaterol, protokylol, reproterol, rimiterol, ritodrine, salbutamol (albuterol), salmeterol, soterenol, terbutaline, tretoquinol, tulobuterol, derivatives and salts thereof.

56. (new) The chemical complex according to claim 54, wherein the aminosugar is glucosamine hydrochloride or glucosamine sulfate.

57. (new) The chemical complex according to claim 54, wherein the beta-2 adrenoceptor agonist is salbutamol sulfate, terbutaline sulfate or formoterol fumarate dihydrate.

58. (new) A composition comprising:

- i) a beta-2 adrenoceptor agonist;
- ii) an aminosugar selected from the group consisting of glucosamine, mannosamine, salts and derivatives thereof, wherein the derivatives thereof is selected from the group consisting of wherein the amino group and/or hydroxyl group of the aminosugar is alkylated, arylated or acylated, and wherein the anomeric, 2-, 3-, 4-, or 6- position is sulphated or phosphorylated; and
- iii) one or more acceptable excipients or carriers.

59. (new) The composition according to claim 58, wherein the beta-2 adrenoceptor agonist is selected from the group consisting of bambuterol, bitolterol, carbuterol, clenbuterol, clorprenaline, dioxethedrine, dopexamine, ephedrine, epinephrine, etafedrine, ethylnorepinephrine, fenoterol, formoterol, hexoprenaline, isoetarine, isoproterenol, mabuterol, metaproterenol, methoxyphenamine, pirbuterol, procaterol, protokylol, reproterol, rimiterol, ritodrine, salbutamol (albuterol), salmeterol, soterenol, terbutaline, tretoquinol, tulobuterol, derivatives and salts thereof.

60. (new) The composition according to claim 58, wherein the aminosugar is glucosamine hydrochloride or glucosamine sulfate.

61. (new) The composition according to claim 58, wherein the beta-2 adrenoceptor agonist is salbutamol sulfate, terbutaline sulfate or formoterol fumarate dihydrate.

62. (new) The composition according to claim 58, wherein the beta-2 adrenoceptor agonist and the aminosugar is in the form of a chemical complex comprising:

i) a beta-2 adrenoceptor agonist; and

ii) an aminosugar selected from the group consisting of glucosamine, mannosamine, salts and derivatives thereof, wherein the derivatives thereof is selected from the group consisting of derivatives wherein the amino group and/or hydroxyl group of the aminosugar is alkylated, arylated or acylated, and wherein the anomeric, 2-, 3-, 4-, or 6-position is sulphated or phosphorylated.

63. (new) The composition according to claim 58, further comprising one or more therapeutically active agents other than a beta-2 adrenoceptor agonist and the aminosugar.

64. (new) The composition according to claim 58 in a form selected from the group consisting of oral formulation, topical formulation, transdermal formulation, and parenteral formulation.

65. (new) A method for the suppression of hypersensitivity and/or inflammatory reactions in a mammal, comprising the administration to said mammal of a combination of a beta-2 adrenoceptor agonist and an aminosugar, or pharmaceutically acceptable salts thereof, the aminosugar being selected from the group consisting of glucosamine, mannosamine, salts and derivatives thereof, wherein the derivatives thereof is selected from the group consisting of wherein the amino group and/or hydroxyl group of the aminosugar is alkylated, arylated or acylated, and wherein the anomeric, 2-, 3-, 4-, or 6-position is sulphated or phosphorylated.

66. (new) The method according to claim 65, for the treatment or prevention of hypersensitivity skin disease in a mammal.

67. (new) The method according to claim 66, for the treatment or prevention of atopic eczema, contact dermatitis, seborrhoeic eczema and/or psoriasis.

68. (new) The method according to claim 66, for the treatment or prevention of contact dermatitis or psoriasis.

69. (new) The method according to claim 65 for the treatment or prevention of IgE mediated allergic reaction and/or condition.

70. (new) The method according to claim 69, for the treatment or prevention of asthma, allergic rhinitis, and/or anaphylaxis .

71. (new) The method according to claim 65 for the treatment or prevention of autoimmune disease and/or chronic inflammatory.

72. (new) The method according to claim 71, for the treatment of autoimmune hepatitis, Primary biliary cirrhosis, Primary sclerosing cholangitis, Autoimmune hemolytic anemias, Grave's disease, Myasthenia gravis, Type 1 Diabetes Mellitus, Inflammatory myopathies, Multiple sclerosis, Hashimoto's thyroiditis, Autoimmune adrenalitis, Crohn's Disease, Ulcerative Colitis, Glomerulonephritis, Progressive Systemic Sclerosis (Scleroderma), Sjögren's Disease, Lupus Erythematosus, Primary vasculitis, Rheumatoid Arthritis, Juvenile Arthritis, Mixed Connective Tissue Disease, Psoriasis, Pemfigus, Pemfigoid or Dermatitis Herpetiformis.

73. (new) The method according to claim 72, for the treatment or prevention of diabetes, Crohn's disease, ulcerative colitis, rheumatoid arthritis, multiple sclerosis, gout or osteoarthritis.

74. (new) The method according to claim 65, wherein the mammal is a human.

75. (new) The method according to claim 65, wherein the combination of the beta-2 adrenoceptor agonist and the aminosugar is a chemical complex comprising:

i) a beta-2 adrenoceptor agonist; and

ii) an aminosugar selected from the group consisting of glucosamine, mannosamine, salts and derivatives thereof, wherein the derivatives thereof is selected from the group consisting of derivatives wherein the amino group and/or hydroxyl group of the aminosugar is alkylated, arylated or acylated, and wherein the anomeric, 2-, 3-, 4-, or 6-position is sulphated or phosphorylated.

76. (new) The method according to claim 65, wherein the combination of a beta-2 adrenoceptor agonist and the aminosugar is a composition comprising:

- i) a beta-2 adrenoceptor agonist;
- ii) an aminosugar selected from the group consisting of glucosamine, mannosamine, salts and derivatives thereof, wherein the derivatives thereof is selected from the group consisting of wherein the amino group and/or hydroxyl group of the aminosugar is alkylated, arylated or acylated, and wherein the anomeric, 2-, 3-, 4-, or 6- position is sulphated or phosphorylated; and
- iii) one or more acceptable excipients or carriers.

77. (new) The method according to claim 65, wherein the combination of a beta-2 adrenoceptor agonist and an aminosugar, or pharmaceutically acceptable salts thereof, are together comprised in a single formulation or are each individually comprised in separate formulations.

78. (new) The method according to claim 65, wherein the combination of a beta-2 adrenoceptor agonist and an aminosugar is administered by means of oral, topical, transdermal, or parenteral administration, or combinations thereof.

79. (new) The method according to claim 77, wherein the separate formulations are administered in a simultaneous or non-simultaneous manner.

80. (new) The method according to claim 65, further comprising administering one or more therapeutically active substances other than the said beta-2 adrenoceptor agonist and said aminosugar.